Phase II Study of Buparlisib in Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia

Trial Profile

Phase II Study of Buparlisib in Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 14 Sep 2017

At a glance

  • Drugs Buparlisib (Primary)
  • Indications Chronic lymphocytic leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 11 Sep 2017 Planned primary completion date changed from 1 Jul 2017 to 1 Dec 2017.
    • 24 Jan 2017 Status changed from recruiting to active, no longer recruiting.
    • 01 Feb 2015 Status changed from not yet recruiting to recruiting, as reported by National Cancer Institute of Canada record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top